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treatment.
The aim was to describe the core differences in regard to image
acquisition and radiologic assessment in OA efﬁcacy studies and studies
assessing a-NGF compounds.
Methods: The current standards in image acquisition and assess-
ment in OA efﬁcacy studies will be reviewed based on the authors’
long-standing involvement in OA trials and the available literature.
In particular, the role of radiography vs. MRI will be brieﬂy
reviewed. These ﬁndings will be contrasted to past and future a-
NGF studies applying radiography and MRI for patient eligibility
and safety monitoring. Differences between expected JSN in OA vs.
rapid progression will be discussed. In addition, the role of MRI as
an adjunct instrument to detect early ﬁndings of relevance will be
emphasized.
Results: In regard to eligibility, OA efﬁcacy studies require semi-
quantitative assessment of screening radiographs to deﬁne disease
severity. Similarly in a-NGF studies, subjects may be included based on
screening radiographs. In addition to standard semiquantitative
assessment, additional pre-deﬁned diagnoses of exclusion have to be
considered, such as atrophic OA, which potentially indicate increased
risk of more rapid progression. In regard to on-study radiologic
assessment, the focus in traditional OA efﬁcacy studies is on maximized
sensitivity to change over time to detect differences in JSN, while in a-
NGF studies the focus lies on maximized sensitivity to detect early
adverse ﬁndings that potentially result in withdrawal from treatment.
Especially in cases of discrepant clinical and radiographic ﬁndings
additional MRI examinations are needed to increase sensitivity to
detect early changes.
Fig. 1. Osteoarthritis efﬁcacy study. A. Baseline image shows medial joint
space narrowing (JSN) (arrows). B. At 2-year follow-up there is an increase
in JSN that is deﬁnite but does not suggest rapid progression
Fig 2. a-NGF study. A. Baseline image shows deﬁnite medial JSN (arrows)
and no osteophytes consistent with atrophic OA. B. At the 9-month fol-
low-up rapid progression in JSN is seen with now bone-to-bone appear-
ance (arrows). Finding is consistent with RPOA Type I.Fig 3. a-NGF study. A. Baseline image shows deﬁnite osteoarthritis
Kellgren-Lawrence Grade III with presence of osteophytes and medial JSN.
B. At the 12-month follow-up severe disintegration of the medial com-
partment including collapse of the tibial plateau is observed. Finding is
consistent with RPOA Type II.
Conclusions: The role of radiologic assessment differs in traditional
efﬁcacy and a-NGF studies. While in traditional efﬁcacy studies image
acquisition and evaluation is optimized for sensitivity to detect minor
changes between treated and non-treated subjects, in a-NGF studies the
focus is on early detection of diagnoses that either puts a subject at
increased risk for an adverse outcome (eligibility) or may result in
withdrawal from treatment (safety).
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CIRCADIAN VARIATION IN SYMPTOMS OF OSTEOARTHRITIS e
POSSIBLE MODIFICATION FROM TREATMENT WITH SEED AND
SHELL CONTAINING POWDER FROM ROSE-HIP
K. Winther, K. Marstrand. Inst. for Clinical Res., Frederiksberg C, Denmark
Purpose: Stiffness and pain from osteoarthritis (OA), is often more
pronounced in the morning than later in the day. When testing treat-
ment of OA symptoms this circadian variation is rarely recognized. The
aim of this study, therefore, was to evaluate the size of change in
stiffness and pain scores from early morning until noon in OA patients.
We also tested if the reduction in stiffness and in pain from treatment, if
any, was more pronounced in the morning than later in the day.
Methods: Stiffness and pain from osteoarthritis (OA), is often more
pronounced in the morning than later in the day. When testing treat-
ment of OA symptoms this circadian variation is rarely recognized. The
aim of this study, therefore, was to evaluate the size of change in
stiffness and pain scores from early morning until noon in OA patients.
We also tested if the reduction in stiffness and in pain from treatment, if
any, was more pronounced in the morning than later in the day.
Results: Morning values for stiffness, group A (placebo ﬁrst): 4.90
þ/-2.30 vs 3.95 þ/- 1.82 at noon, a drop of 20% (p<0.000). Pain insig-
niﬁcantly declined by 5%. Testing the A group after a further 3 month on
active therapy resulted in a similar pattern - a signiﬁcant drop in stiff-
ness comparing morning and noon (p<0.035) a drop but not signiﬁcant
in pain. Group B (active treatment ﬁrst - then placebo): morning stiff-
ness 4.56 þ/- 2.01 vs 3.68 þ/- 1.86 at noon. A drop of 20% (p<0.000).
Pain: 4.27 þ/- 2.06 in the morning vs 3.60 þ/- 1.80 at noon, a 16%
reduction (p<0.000). A similar pattern was seen testing after 3 month
placebo. Lumping groups together (n¼47) did not alter conclusions
(data not given). When the A group was tested in the morning, active
treatment resulted in a signiﬁcant reduction of 20% (p<0.002) when
compared to placebo. This reduction was 10% and still signiﬁcant when
testing at noon (p<0.037). The delta decline in stiffness in the morning
caused by active treatment was 0.95 þ/- 1.46 as compared to noon, 0.39
þ/- 0.97 (p<0.046). Active treatment reduced pain by 15.5% (p<0.013) in
the morning corresponding to a similar reduction at noon: 15.9%
(p<0.055). No signiﬁcant change comparing time of day. In the B group
(active ﬁrst) there were no signiﬁcant changes in any of the parameters
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niﬁcant drop in stiffness in the morning as well as at noon, (p<0.030)
and (p<0.035), respectively, with no time difference in between. Pain
showed identical pattern: p values morning <0.020 and noon <0.015,
no time dependency. In accordance with the drop in stiffness and pain
active treatment also resulted in an signiﬁcant improved quality of
sleep, improved mood and a better wellbeing (data not given).
Conclusions: Stiffness and to some degree pain was most pronounced
in themorning. The present Rose-hip powder seemsmore potent, when
symptoms are more pronounced. This may explain improved sleeping
quality observed during active treatment. Circadian variation should be
recognized in OA patients.
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TISSUEGENE-C (INVOSSA™) IN PATIENTS WITH OSTEOARTHRITIS: A
PHASE II TRIALS
J. Cho, T. Kim, Y. Park, B. Lee. Kolon Life Sci., GwaChun, Republic of Korea
Purpose: TissueGene-C (TG-C) is a cell mediated gene therapy that
contains non-transduced (hChonJ) and transduced (hChonJb#7) human
allogeneic chondrocytes. The hChonJb#7 cells were transduced with
TGF-b1 gene by using retroviral vector and irradiated with gamma-ray.
TG-C has been demonstrated its efﬁcacy and safety in preclinical studies
in vitro and in vivo. TG-C has been proven for its safety and efﬁcacy in
Phase I and Phase IIa clinical studies in osteoarthritis (OA) patients.
The current placebo controlled phase IIb study was conducted to
determine both safety and efﬁcacy of TG-C in patients with OA of the
knee.
Methods: Participants (n ¼ 54) with a conﬁrmed diagnosis of knee OA
by X-ray and MRI were randomized into the treatment group (TG-C,
1.8x107cells/knee, n ¼ 27) and the placebo group (saline, n ¼ 27). The
primary evaluation parameter was International Knee Documentation
Committee (IKDC) which measures pain, sports activities, and daily
function. The secondary evaluation parameters were Western-Ontario
and MacMaster University (WOMAC) score, Knee Injury and Osteo-
arthritis Outcome Score (KOOS), and 100 mm Visual Analogue Scale
(VAS). These parameters were assessed at 12 and 24 weeks post
treatment. For TG-C treatment group, the evaluation was extended to
48 weeks post treatment.
Additionally, changes in biomarkers were assessed in serum and urine
samples. Safety measures, including physical exams, complete blood
count, and serum chemistry were included up to 6 months post treat-
ment. Blood samples were screened to detect the replication competent
retrovirus (RCR), retrovirally transduced cells, and TGF-b1 DNA and
protein starting from 2 weeks up to 6 months post treatment.
Results: TG-C treatment group showed improvement in IKDC, WOMAC,
KOOS and 100 mm VAS scores compared to placebo group, which was
maintained up to the 1 year.
Conclusions: In summary, the Phase IIb study indicated that TG-C
(InvossaTM) treatment improved pain, sports activities, and quality of
daily life in patients with knee OA when compared to the placebo
control.
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ROSE-HIP INCLUDING SEEDS AND SHELLS REPORTED TO REDUCE
SYMPTOMS OF OSTEOARTHRITIS, IMPROVES QUALITY OF THE SKIN
BY MECHANISMS WHICH MAY INVOLVE COLLAGEN AND
LONGEVITY OF CELL MEMBRANES
K. Winther, L. Petcharat, K. Wongsuphasawat. Inst. for Clinical Res.,
Frederiksberg C, Denmark
Purpose: Rose-hip powder, containing seeds and shells, rich in a gal-
actolipid, GOPO, was shown to alleviate pain and stiffness in osteo-
arthritis and inhibit MMP-1, an enzyme breaking down collagen, in the
cartilage of joints and in the subcutaneous tissue of the skin, causing
wrinkles. Collagen is supported by anti-oxidants including Vitamin C.
Anti-oxidants can also improve the longevity of cell membranes. Ani-
mal studies show that natural vitamin C given as part of dried rose-hip
powder is absorbed better than artiﬁcial vitamin C. The aim of this study
was to test, if the present Rose-hip powder would have any impact on
the depth of wrinkles of the face (craw feet), if natural vitamin C as part
of rose-hip powder was absorbed better than artiﬁcial vitamin C and if
the present powder would add to the longevity of cell membranes.Methods: A number of 34 healthy volunteers, 35 - 65 years of age, were
randomly allocated to 2 month oral treatment with either the strong
anti-oxidant Astaxanthin 4 mg daily, well known for its reduction of
wrinkels (n¼17) or the present standardized rose-hip powder (Hyben-
Vital®) 3 g daily (n¼17) in a blinded manner. The depth of wrinkles was
estimated initially and after 8 weeks, using a Skin Visioscan ® VC98.
Another group of 16 healthy volunteers were given either a single dose
of 15 g of the present rose-hip powder, equivalent to 125 mg of natural
vitamin C or a single dose of 250 mg of artiﬁcial vitamin C. Blood levels
of vitamin C was estimated initially and after 1, 2, 4 and 6 hours using
photometric methodology. Eighteen other healthy volunteers were
treated with Rose-hip powder 45 g daily for 28 days. Red cells were
isolated before and after 14 and 28 days of treatment, respectively, and
again one month after stopping treatment. Each portion of blood was
stored in a blood bank for 5 weeks. Then the leak of haemoglobin (HGB)
from red cells into the surrounding medium, indicating cell membrane
disintegration, was measured. TheWilcoxon test was used for statistical
evaluation within groups. Mann-Whitney for differences between
groups. Data given is mean þ/-sd.
Results: Astaxanthin as well as Rose-hip signiﬁcantly reduced the
depth of wrinkels: Visioscan index initially: Astaxanthin 46.1 þ/- 7.8 vs
two month 42.2 þ/- 5.5 (p < 0.003). Rose-hip resulted in a similar and
signiﬁcant reduction of wrinkles: 45.9 þ/-9.9 vs 42.1 þ/- 5.4 (p<0.034).
No difference between groups (Mann-Whitney p value p<0.995).
Patients reported that theywere equally satisﬁed by the two treatments
(data not given). The lower dose of natural vitamin C (125 mg) given as
rose-hip powder resulted in an improvement from 76.85 þ/- 23.0
peaking after two hours 122.15 þ/- 14.4 mmol/l (p<0.010). A similar
pattern was seen when using the double dose of artiﬁcial vitamin C:
initial level 71.7 þ/- 25.6 peaking after 2 hours 119.1 þ/- 21.0 mmol/l
(p<0.010). No signiﬁcant difference comparing groups. The leak of HGB,
from erythrocytes, signiﬁcantly declined during Rose-hip treatment.
Initial value 57.2 þ/-13.9 vs 2 weeks treatment 49.2 þ/-16.2 (p<0.01).
One month after stopping treatment, HBG levels were back to initial
values (p<0.010).
Conclusions: The present data suggest that Rose-hip powder con-
taining seeds and shells can have some impact on the protection of
collagen and that vitamin C given in its natural form as a part of dried
rose-hip powder is better absorbed than artiﬁcial vitamine C. The
present rose-hip powder seems to improve the longevity of cell
membranesEpidemiology
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THE PREVALENCE AND DIAGNOSTIC ACCURACY OF CLINICAL EXAM
TESTS IN IDENTIFYING RADIOGRAPHIC FEMOROACETABULAR
IMPINGEMENT (FAI): A PROSPECTIVE POPULATION-BASED STUDY
C. Ratzlaff y, L. Li z, H. Wong z, J. Kopec z, C. Zhang z, J. Esdaile z,
H. Qian z, M. Barber z, B. Forster z. yBrigham and Women's Hosp. /
Harvard Med. Sch., Boston, MA, USA; zUniv. of British Columbia,
Vancouver, BC, Canada
Purpose: Femoroacetabular impingement (FAI) is common and some-
times associated with hip pain, labral and chondral pathology and
osteoarthritis. The gold standard for diagnosis for bony FAI is specialized
radiographic views and/or speciﬁc MRI sequences.
Currently, no physical examination tests can accurately conﬁrm or
discard the presence of radiographic FAI. A recent systematic review
found a critical absence of high quality studies and was unable to
provide a clinical recommendation (Tijssen et al 2012). Almost all
previous studies suffer from spectrum bias (most subjects had hip
pathology) and the majority of studies from small samples.
The objective was to undertake the largest, and ﬁrst population-based
study to estimate the prevalence and diagnostic accuracy of physical
exam tests in identifying radiographic FAI in Caucasian and Chinese
samples
Methods: A random population-based sample of 711 subjects (510
Caucasian and 201 Chinese) was recruited in Vancouver, Canada. The
sample was stratiﬁed on the presence/absence of hip pain to recruit
equal numbers of both. Individuals between 20 and 49 years were eli-
gible if they reported both parents were of Caucasian or Chinese
descent and could attend a two-hour session, consisting of physical
